CSPC Pharmaceutical Group Limited
1093.HKApprovedCSPC Pharmaceutical Group is a leading Chinese pharmaceutical company with a diversified portfolio spanning innovative drug development, generic medicines, and pharmaceutical manufacturing. Founded in 1997 and publicly traded on the Hong Kong Stock Exchange, the company has established itself as a major player in China's pharmaceutical industry with strong R&D capabilities and extensive manufacturing infrastructure. CSPC focuses primarily on oncology, CNS disorders, and metabolic diseases, with multiple products in clinical development and a robust commercial portfolio serving both domestic and international markets.
1093.HK · Stock Price
Historical price data
AI Company Overview
CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company with a diversified portfolio spanning innovative drug development, generic medicines, and pharmaceutical manufacturing. Founded in 1997 and publicly traded on the Hong Kong Stock Exchange, the company has established itself as a major player in China's pharmaceutical industry with strong R&D capabilities and extensive manufacturing infrastructure. CSPC focuses primarily on oncology, CNS disorders, and metabolic diseases, with multiple products in clinical development and a robust commercial portfolio serving both domestic and international markets.
Technology Platform
Integrated pharmaceutical platform combining small molecule and biologics development with advanced drug delivery systems and manufacturing capabilities.
Pipeline Snapshot
77 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Butylphthalide + Butylphthalide placebo | ST-segment Elevation Myocardial Infarction (STEMI) | Phase 3 | |
| pegylated liposomal doxorubicin (PLD) + PD-1 | Muscle Invasive Bladder Cancer | Phase 2 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitab... | Leukemia, Myeloid, Acute | Phase 2 | |
| Sintilimab + Nab paclitaxel + Cisplatin | Esophageal Squamous Cell Carcinoma | Phase 2 | |
| Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabin... | B-cell Acute Lymphoblastic Leukemia | Phase 2 |
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
CSPC competes with leading Chinese pharmaceutical companies like Jiangsu Hengrui and international players, differentiating through its strong neurological and oncology portfolios and cost-effective operations.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile